Baxter Theranova: More Middle Molecules, Less Albumin Loss
Baxter’s new dialyzer mimics the function of natural kidneys more closely, removing more middle molecules with no replacement fluid needed—and minimal loss of vital albumin. The new expanded hemodialysis (HDx) therapy has been tested in the UK, where it reduced beta-2 microglobulin levels by more than 11%
Read the full article » | Posted 12-14-2017
Related Articles
- Proof of Concept for Silicon Nanopore Membrane Implantable HD Posted 10-05-2026
- AWAK PD To Go Posted 10-05-2026
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026

